Acute myocardial infarction, reperfusion injury, and intravenous magnesium therapy: basic concepts and clinical implications

Am Heart J. 1996 Aug;132(2 Pt 2 Su):478-82; discussion 496-502. doi: 10.1016/s0002-8703(96)90339-7.

Abstract

The concept of reperfusion-induced injury has aroused special interest during the past decade as thrombolysis and direct angioplasty were introduced for early restoration of coronary blood flow in patients with acute myocardial infarction. There is experimental and clinical evidence that oxygen-derived free radicals (oxyradical hypothesis), activation of the complement system (complement hypothesis), and disturbance in calcium homeostasis (calcium hypothesis), may account for the development of reperfusion injury. Data from numerous animal experiments and clinical trials suggest that magnesium, a physiologic calcium blocker, may be efficacious for reduction of reperfusion injury. Despite encouraging results from previous clinical trials that revealed beneficial effects of intravenous magnesium therapy with respect to mortality, left ventricular function, and infarct size, a recently published large-scale trial (ISIS-4) provided conflicting data and caused major controversy. Further clinical trials, well-designed and carefully conducted, should elucidate the beneficial effects of magnesium in acute myocardial infarction, especially in conjunction with new and aggressive reperfusion techniques.

Publication types

  • Review

MeSH terms

  • Calcium Channel Blockers / pharmacology
  • Calcium Channel Blockers / therapeutic use*
  • Heart / drug effects
  • Humans
  • Magnesium Sulfate / pharmacology
  • Magnesium Sulfate / therapeutic use*
  • Myocardial Infarction / drug therapy*
  • Myocardial Reperfusion Injury / physiopathology*
  • Myocardial Reperfusion Injury / prevention & control

Substances

  • Calcium Channel Blockers
  • Magnesium Sulfate